Johnson & Johnson (JNJ)
ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook
IHE, PPH, XLV, IYH and FTXH could gain as JNJ lifts 2025 outlook and dividend after strong Q2 earnings beat.
Johnson & Johnson (JNJ) Q2 Earnings and Revenues Top Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings of $2.82 per share a year ago.
Johnson & Johnson (JNJ) Surpasses Q2 Earnings and Revenue Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings of $2.82 per share a year ago.
JNJ's Stock Price Is Back in Rally Mode—The Time to Buy Is Now
After years of post-COVID-19 normalization and the impact of its Kenvue spinoff, Johnson & Johnson's NYSE: JNJ stock price is back in rally mode. It is still early in the game, but the Q2 results affirm that growth is back, acceleration is happening and is expected to continue in the back half of the year.
Johnson & Johnson (JNJ) Q2 2025 Earnings Call Transcript
Johnson & Johnson (NYSE:JNJ ) Q2 2025 Earnings Conference Call July 16, 2025 8:30 AM ET Company Participants Darren Snellgrove - Corporate Participant Jennifer L. Taubert - Executive VP & Worldwide Chairman of Innovative Medicine Joaquin Duato - CEO & Chairman John C.
2 Dividend Giants Every Passive Income Investors Should Own
It's never been easier as a passive income investor to give your yield a bit of a jolt with the rise of covered call (and premium income) ETFs that trade off a bit of upside potential for some premiums.
Johnson & Johnson Stock Jumps on Strong Earnings, Higher Outlook
Johnson & Johnson (JNJ) shares surged Wednesday after the company reported second-quarter results that topped estimates and the company lifted its full-year outlook.
JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise
JNJ tops second-quarter estimates and raises 2025 guidance as Innovative Medicines outperforms and MedTech gains momentum.
Johnson & Johnson (JNJ) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Johnson & Johnson (JNJ) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
J&J CFO Joseph Wok on Q2 results: 2025 is shaping up to be better than what we'd thought
Johnson & Johnson executive vice president and CFO Joseph Wolk joins 'Squawk Box' to discuss the company's quarterly earnings results, raising FY guidance, drug pipeline outlook, and more.
Johnson & Johnson Tops Q2 Estimates, Lifts Outlook for Sales and Profit
Johnson & Johnson (JNJ) on Wednesday lifted its full-year projections and reported second quarter results that beat estimates.
Johnson & Johnson (NYSE: JNJ) Live Earnings Updates: Will The Dividend Champion Deliver?
Johnson & Johnson reports before the bell today. The stock is popular in part thanks to its 3.3% dividend yield.
